Conventional approaches for certain cancer patients treatment are using drugs or specialized medical instrument with therapeutical means (radiation, heat, ect.) Recently, a targeting molecule (drug) conjugated with a radionuclide offers a personalized treatment for a internal radiation therapy.The most updated status is on phase III in U.S.. An eye-catching news is not merely from scientific and clinical results but on the battleground a business real deal between Bayer and Algeta.
This is a $800M transaction and Algeta received $61M upfront payment. Algeta is a Nordic public company and shares trading at many stock exchange markets. Less than 50 employees work for this company. Even the Eurozone encountered a string of economic drawbacks, Algeta was successful on latest fund raising and appealing Big partner (pharma).
by alveice Team (alveice@gmail.com)
This is a $800M transaction and Algeta received $61M upfront payment. Algeta is a Nordic public company and shares trading at many stock exchange markets. Less than 50 employees work for this company. Even the Eurozone encountered a string of economic drawbacks, Algeta was successful on latest fund raising and appealing Big partner (pharma).
by alveice Team (alveice@gmail.com)
Beside of radioactive iodine labeled anti-CD20 antibody (Bexxar_I131), different nuclides (I111 and Y90) applied on the same antobody is under evaluation.
ReplyDeletePhase II Trial of Short-Course R-CHOP Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients. (Clin Cancer Res. 2010 Jun 11. )
Internal Yttrium-90 combined 5-Fu showed better response rate for liver metastasis
ReplyDeletePhase III Trial Comparing Protracted Intravenous Fluorouracil Infusion Alone or With Yttrium-90 Resin Microspheres Radioembolization for Liver-Limited Metastatic Colorectal Cancer Refractory to Standard Chemotherapy.
J Clin Oncol. 2010 Jun 21.